Ireland - English - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals (ireland) ltd - haloperidol - solution for injection - 5 milligram(s)/millilitre - butyrophenone derivatives; haloperidol

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - haloperidol decanoate, quantity: 70.52 mg/ml (equivalent: haloperidol, qty 50 mg/ml) - injection, solution - excipient ingredients: benzyl alcohol; sesame oil - haldol decanoate is indicated for the maintenance therapy of psychoses in adults; particularly for patients requiring prolonged parenteral neuroleptic therapy

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - haloperidol - solution for injection - 5mg/1ml

United States - English - NLM (National Library of Medicine)

patriot pharmaceuticals llc - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol 50 mg in 1 ml - haloperidol decanoate 50 and haloperidol decanoate 100 are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate 50 and haloperidol decanoate 100 are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions). - parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies). - dementia with lewy bodies (see warnings, neurological adverse reactions in patients with parkinson's disease or

United States - English - NLM (National Library of Medicine)

gland pharma limited - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol 50 mg in 1 ml - haloperidol decanoate injection, 50 mg/ml and haloperidol decanoate injection, 100 mg/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection, 50 mg/ml and 100 mg/ml are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: • severe toxic central nervous system depression or comatose states from any cause. • hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions ). • parkinson’s disease (see warnings, neurological adverse reactions in patients with parkinson’s disease or dementia with lewy bodies ). • dementia with lewy bodies (see warnings, neurological adverse

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol 50 mg in 1 ml - haloperidol decanoate injection, 50 mg/ml and haloperidol decanoate injection, 100 mg/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection, 50 mg/ml and 100 mg/ml are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions ). - parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies ). - dementia with lewy bodies (see warnings, neurological adverse reactions in

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - haloperidol decanoate, quantity: 70.52 mg/ml (equivalent: haloperidol, qty 50 mg/ml) - injection, solution - excipient ingredients: sesame oil; benzyl alcohol - haldol decanoate is indicated for the maintenance therapy of psychoses in adults; particularly for patients requiring prolonged parenteral neuroleptic therapy.

United States - English - NLM (National Library of Medicine)

tya pharmaceuticals - haloperidol (unii: j6292f8l3d) (haloperidol - unii:j6292f8l3d) - haloperidol 5 mg in 1 ml - haloperidol is indicated for use in the treatment of schizophrenia. haloperidol is indicated for the control of tics and vocal utterances of tourette's disorder. haloperidol is contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this drug or have parkinson's disease.

United States - English - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - haloperidol lactate (unii: 6387s86pk3) (haloperidol - unii:j6292f8l3d) - haloperidol 5 mg in 1 ml - haloperidol is indicated for use in the treatment of schizophrenia. haloperidol is indicated for the control of tics and vocal utterances of tourette's disorder. haloperidol is contraindicated in severe toxic central nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this drug or have parkinson's disease.

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - haloperidol lactate (unii: 6387s86pk3) (haloperidol - unii:j6292f8l3d) - haloperidol 5 mg in 1 ml - haloperidol injection, usp is indicated for the treatment of patients with schizophrenia. haloperidol injection is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions ). - parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies ). - dementia with lewy bodies (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies ).